USPTO Patent Applications - Therapeutics (A61P)

Methods Of Treating Plantar Fibromatosis

The USPTO published patent application US20260091093A1 disclosing methods of treating plantar fibromatosis. The application (No. 19288249) was filed August 1, 2025, and names five inventors including James P. Tursi and Jeffrey David Lehrman. The invention relates to therapeutic methods using compositions classified under A61K 38/4886.

BabA Antibodies for Preventing H. pylori Gastric Disease

USPTO published patent application US20260091099A1 by inventors Borén and Hammarström covering recombinant blood group antigen-binding adhesin (BabA) compositions that raise antibodies targeting conserved epitopes in the Leb antigen binding domain of BabA. The application discloses methods for preventing H. pylori-associated gastric diseases including gastric cancer, peptic ulcers, and gastritis without eradicating the infection.

Mycobacterium Vaccine Compositions for Immune System Modulation

The USPTO published patent application US20260091098A1 by inventor Bruce S. Gillis covering methods and compositions using killed or inactivated Mycobacterium or antigenic fragments for modulating immune system function. The application was filed September 12, 2025, under Application No. 19327636. This is a published patent application and does not grant any rights or impose obligations on third parties at this time.

Methods Of Treating Plantar Fibromatosis

The USPTO published patent application US20260091092A1 on April 2, 2026, disclosing methods of treating plantar fibromatosis. The application (No. 19288073) was filed August 1, 2025, with inventors James P. Tursi, Luis A. Ortega, Qinfang Xiang, Saji Vijayan, Jeffrey David Lehrman, and David Hernandez. The patent covers therapeutic approaches using compounds classified under A61K 38/4886 and A61K 9/0019.

4-Hexylresorcinol pharmaceutical composition for bone disease treatment

The USPTO published patent application US20260091001A1 filed by Kyungpook National University Industry-Academic Cooperation Foundation for a pharmaceutical composition comprising 4-hexylresorcinol (4-HR) as an active ingredient for the prevention or treatment of bone diseases, including osteoporosis. The application claims formulations including ointments that demonstrated improved bone thickness, density, and strength in osteoporosis-induced animal models by promoting osteoblast differentiation and suppressing osteoclast proliferation.

Incretin Analog Dosing and Composition Methods for GLP-1 GIP GCG Tri-Agonists

The USPTO published patent application US20260091088A1 disclosing dosing regimens and compositions for long-acting incretin analogs comprising glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon (GCG) tri-receptor agonists suitable for once-weekly administration. The application covers methods for treating metabolic conditions including obesity (A61P 3/04) and diabetes (A61P 3/10).

Incretin analog tri-receptor agonist compositions for weekly dosing

USPTO published patent application US20260091087A1 disclosing dosing regimens and compositions for long-acting incretin analog tri-receptor agonists targeting GIP, GLP-1, and glucagon receptors for once-weekly administration. The application (No. 19393199) was filed November 18, 2025, and names Tamer Coskun, Zvonko Milicevic, and Shweta Urva as inventors.

P55gamma as Therapeutic Target for Aortic Dissection

The USPTO published patent application US20260091091A1 claiming p55γ as a therapeutic target for aortic dissection (AD). The inventors from China demonstrated that p55γ overexpression inhibits AD formation and elastic fiber degradation in β-aminopropionitrile fumarate (BAPN)-induced mouse models. The patent covers using p55γ as a screening target for drugs to prevent and/or treat AD.

Halogenated Phenol Antimicrobial Composition

The USPTO published patent application US20260091002A1 filed by Industry Academic Cooperation Foundation of Yeungnam University for a halogenated phenol derivative composition with antimicrobial and antibiofilm activity against Staphylococcus aureus and pathogenic microorganisms. The application, filed June 10, 2025, covers the composition, methods of use, and treatment of biofilm-related infections.

Cat Food Composition for Treating or Preventing Urolithiasis

The USPTO published patent application US20260090570A1 for a cat food composition designed to treat or prevent urolithiasis (urinary stones) in cats. The wet and dry compositions include omega-3 fatty acids from flaxseed and fish oil, along with pH-modifying ingredients such as calcium sulfate, methionine, sodium acid pyrophosphate, taurine, and potassium sulfate. The application was filed on October 1, 2024, under application number 18903721.

Cat Food Composition for Treating Urolithiasis and Reducing Hairballs

The USPTO published patent application US20260090571A1 for a cat food composition targeting urolithiasis (urinary stones) and hairball reduction. Inventors Nolan Z. Frantz, Angela M. Gajda, and Todd Harper developed wet and dry formulations incorporating omega-3 sources (flaxseed, fish oil), acidifiers (calcium sulfate, SAPP), methionine, taurine, and dietary fiber to achieve urine pH between 6.15-6.85 and reduce RSS struvite to ≤1.8 and RSS oxalate to ≤6.0.

Urolithin oral care compositions patent application

USPTO published patent application US20260090966A1 for urolithin-based oral care compositions including toothpaste, mouthwash, gels, and chewing gum with therapeutic or cosmetic effects. The application covers compositions comprising urolithins, methods of treatment, and formulations with additional active ingredients such as fluoride. Inventors include Christopher L. Rinsch, Davide D'Amico, Anurag Singh, and Charlotte Tissot.

LifeActive Transdermal Delivery Formulations Patent Application

USPTO published patent application US20260090982A1 for LifeActive, Inc., covering transdermal delivery formulations for therapeutic agents, drugs, and nutrients. Inventors include Calvin Dexter Morris, Burgess A. Thomasson Jr., and Scott A. Jenkins. The application discloses homogeneous transdermal formulations combining weak organic acid accelerants with fatty acid microemulsions for enhanced skin absorption.

Aspirin Oral Mucosal Formulations

USPTO published patent application US20260090985A1 for oral mucosal aspirin formulations (91-200mg micronized) with buffer and surfactant components. The application, filed by inventor James Dzandu, covers sublingual and buccal delivery formulations with pH ≤3. No regulatory obligations or compliance deadlines are imposed by this patent publication.

Cannabinoid Emulsion Compositions for Treating Ophthalmic Conditions

Rhodes Technologies published patent application US20260090988A1 for stable cannabinoid emulsion compositions designed for ocular delivery to treat ophthalmic conditions including glaucoma. The application, filed July 29, 2025, and published April 2, 2026, names inventors Ping Chang, Zhenze Hu, and Yuanyuan Tao. This publication represents a patent application only and does not grant enforceable patent rights.

Orodispersible Estetrol Dosage Unit Patent

USPTO published patent application US20260090995A1 by ESTETRA SRL covering an orodispersible solid pharmaceutical dosage unit containing estetrol particles (0.1-25 wt.%) for sublingual, buccal, or sublabial administration. The dosage unit weighs 30-1,000 mg, contains at least 100 μg of estetrol component, and is manufactured via wet granulation of particles sized 2-50 μm. Application No. 19340502 was filed September 25, 2025.

Delayed Release IBD Treatment Composition

Aihol Corporation filed patent application US20260090996A1 for a delayed-release oral pharmaceutical composition containing mesalamine and hyaluronan layers for treating inflammatory bowel disease. The USPTO published the application on April 2, 2026, with Application No. 19399068 and a filing date of November 24, 2025. This patent covers novel multi-layer coating technology for targeted drug delivery to the colon.

Polymer Nanoparticle Compositions for NF1 Treatment

The USPTO published patent application US20260090998A1 covering methods of using block copolymer nanoparticles for delivering nucleic acids to treat Neurofibromatosis Type 1 (NF1). The application (filed October 2, 2025) names 12 inventors and discloses compositions and methods for in vivo therapeutic delivery using polymer nanoparticles.

Patent Application: Bifidobacterium longum for Infant Infection Prevention

The USPTO has published a patent application (US20260083785A1) detailing the use of Bifidobacterium longum transitional microorganisms to prevent or reduce the risk of infection in infants and young children. The application was filed on September 27, 2023.

GABA-producing bacteria for improving health patent application

The USPTO has published a new patent application (US20260083786A1) detailing a composition comprising Lactobacillus brevis (NCIMB 41903) for use in regulating or treating metabolic diseases. The application was filed on September 17, 2025, by inventors Paul Ross and Catherine Stanton.

Antiviral Fungal Extracts Prevent Coronavirus Infections

The USPTO has published a patent application (US20260083788A1) detailing antiviral fungal extracts that may prevent coronavirus infections by interfering with the Spike protein. The application, filed by Mycotech Pharma AS, describes compositions derived from Agaricus blazei, Grifola frondosa, and Hericium erinaceus.

Formulation for Hair Growth

The USPTO has published a new patent application, US20260083789A1, for a formulation designed to stimulate hair growth and improve hair quality. The formulation primarily utilizes a nitrate-enriched extract of Amaranth, along with other plant-based ingredients. The application details the method of preparation and its potential use in enhancing hair growth rate, count, and density.

Patent Application: Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083791A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety, food cravings, and stress, and improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Cravings

The USPTO has published a new patent application (US20260083792A1) for methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, food cravings, and improve mood and overall health. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application: Dichrostachys glomerata for Anxiety and Stress Reduction

The USPTO has published a patent application (US20260083793A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, and food cravings, while improving mood and energy. The application was filed on September 25, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata Health Benefits

The USPTO has published a patent application (US20260083794A1) detailing methods and compositions using Dichrostachys glomerata for various health benefits, including reducing anxiety and improving mood. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Stress

The USPTO has published a new patent application (US20260083796A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, stress, and food cravings, while improving mood and overall health in mammals. The application was filed on September 26, 2024, by inventor Shil Kothari.

Patent Application for Dichrostachys glomerata to Reduce Anxiety and Improve Mood

The USPTO has published a patent application (US20260083797A1) detailing methods and compositions using Dichrostachys glomerata to reduce anxiety, food cravings, and stress, and to improve mood, energy, and overall health in mammals. The application was filed on September 26, 2024.

US Patent Application for Heart Boosting Formulation

The USPTO has published a new patent application (US20260083806A1) for a heart boosting formulation. The application details a specific composition including L-carnitine, alpha-linolenic acid, citrulline, vitamin D3, lycopene, holy basil, cinnamon, and beetroot, along with related manufacturing methods. The filing date was September 16, 2025.

Patent Application: Reducing Food Intake Using Plants

The USPTO has published a new patent application (US20260083809A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce food intake or appetite in mammals. The application was filed on September 26, 2024, and is expected to be published on March 26, 2026.

Patent Application: Reducing Visceral Fat Using Plants and Spices

The USPTO has published a new patent application (US20260083810A1) detailing methods and compositions for reducing visceral fat in mammals using plants and spices such as Dichrostachys glomerata or Cissus quadrangularis. The application was filed on September 26, 2024, and is scheduled for publication on March 26, 2026.

Patent Application: Reducing Blood Lipids Using Plants

The USPTO has published a patent application (US20260083811A1) detailing methods and compositions for reducing blood lipids using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes compositions aimed at increasing GLP-1 levels and reducing visceral fat, food intake, blood lipids, total cholesterol, and total glucose.

Patent Application: Reducing Fasting Blood Glucose Using Plants

The USPTO has published a new patent application detailing methods and compositions for reducing fasting blood glucose using plants like Dichrostachys glomerata or Cissus quadrangularis. The application, filed on September 26, 2024, describes oral dosage forms for health benefits including increased GLP-1 levels and reduced blood lipids.

Patent Application for Reducing DPP-4 Activity with Plants

The USPTO has published a new patent application (US20260083813A1) detailing methods and compositions using plants like Dichrostachys glomerata or Cissus quadrangularis to reduce DPP-4 activity or levels in mammals. The application was filed on September 26, 2024.

USPTO Patent Application for Dietary Supplement Formulation

The USPTO has published a patent application (US20260083814A1) for a dietary supplement formulation designed to alleviate sciatica pain and support nerve and musculoskeletal health. The application details a specific blend of natural ingredients and their purported benefits, filed on September 26, 2024.

Patent Application for Cancer Treatment Combination Therapies

The USPTO has published a new patent application (US20260083816A1) detailing methods for treating cancer using combination therapies. The application, filed by inventors Erlinda M. Gordon and Fredrick L. Hall, focuses on inhibiting cyclin proteins and targeting pathways that promote cyclin activity.

Cancer Treatment Using TTFields and Interferon Gamma Compositions

The USPTO has published a new patent application detailing compositions, systems, and methods for treating cancer using Tumor Treating Fields (TTFields) in combination with interferon gamma. The application, filed on September 18, 2025, outlines a method for reducing cancer cell viability and tumor volume.

Patent Application: Autism Symptom Treatment via Neurotensin Receptor Activation

The USPTO has published a new patent application (US20260083820A1) from the New York Institute of Technology for methods and formulations to treat autism symptoms by activating neurotensin receptor 1 (NTSR1) without causing significant lethargy. The application was filed on October 3, 2025.

Ocular Insulin Delivery Enhanced by Prostaglandin Analogues Patent Application

The USPTO has published a patent application (US20260083822A1) for a novel ocular insulin delivery system. The invention utilizes prostaglandin analogues to enhance insulin permeability across ocular tissues, offering a non-invasive alternative to injections for therapeutic effects.

Wound healing composition with amino acids and fish collagen

The USPTO has published a new patent application detailing a composition for promoting wound healing. The composition includes an amino acid mixture and fish collagen, with a method for its administration also described. This application was filed on September 20, 2024.

Novel agent for Alzheimer's treatment using dynamin 1 peptide

The USPTO has published a new patent application (US20260083826A1) from the Okinawa Institute of Science and Technology School Corporation for a novel agent to treat Alzheimer's disease. The application describes a peptide corresponding to dynamin 1, potentially encapsulated in nanoparticles for improved brain delivery.

Patent Application for DNase Enzyme Therapy for Tumor Microenvironment Immunomodulation

The USPTO has published a patent application (US20260083827A1) filed by CLS THERAPEUTICS LIMITED for methods of immunomodulating the tumor microenvironment using DNase enzyme therapy. The application details methods involving the administration of DNase enzyme, alone or with other agents, to combat immunosuppressive tumor cell microenvironments.

Patent Application for Biodegradable Particles Delivering Therapeutic Agents

The USPTO has published a new patent application (US20260083830A1) for biodegradable polymeric particles designed for the extended, controlled release of positively charged therapeutic agents at neutral pH. The application details microparticles and nanoparticles comprising an uncapped polymer matrix and a net positively charged therapeutic agent.

USPTO Patent Application for WNT-Related Cancer Vaccines

The USPTO has published a patent application (US20260083831A1) filed by Geneos Therapeutics, Inc. The application details compositions and methods for treating WNT-related cancers using nucleic acid sequences encoding tumor-specific antigens, potentially in combination with checkpoint inhibitors.

Patent Application: Vaccine for Bordetella pertussis using antigen peptides

The USPTO has published a patent application (US20260083833A1) for a vaccine against Bordetella pertussis using antigen peptides. The application details a method for preventing infection by targeting specific peptides processed and presented by CD4+ T cells. This relates to ongoing research and development in vaccine technology.

Adjuvant Composition with STING Agonist and Aluminium Hydroxide

The USPTO has published a patent application by GlaxoSmithKline Biologicals SA for an adjuvant composition comprising a STING agonist and an aluminum-based adjuvant. The application details immunogenic compositions and their use in immunizing subjects.

Immune Cells Target EpCAM for Tumor Treatment

The USPTO has published a patent application (US20260083843A1) from SUZHOU IMMUNOHEAD BIOTECHNOLOGY CO., LTD. The application details the use of immune cells that target EpCAM for the prevention or treatment of metastatic tumors expressing EpCAM.

Cellicure, Inc. Patent Application for Engineered Immune Cells

The USPTO has published a patent application (US20260083845A1) filed by Cellicure, Inc. on September 22, 2023. The application details engineered immune cells, specifically chimeric antigen receptors (CARs) for enhanced killing activities, primarily targeting cancer treatment.

USPTO Patent Application: Polynucleotides Targeting NR4A3

The USPTO has published a patent application (US20260083846A1) filed by Lyell Immunopharma, Inc. The application describes polynucleotides designed to target the NR4A3 gene and their potential use in treating diseases, including cancer. The patent is scheduled to be published on March 26, 2026.

Patent Application: T-cell receptors target mutant RAS for cancer treatment

The USPTO has published patent application US20260083847A1 concerning T-cell receptors and compositions for treating cancer associated with mutant RAS. The application details methods and compositions involving T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.